This article provides a comprehensive analysis of the Benchmark Dose (BMD) and No-Observed-Adverse-Effect Level (NOAEL) approaches in human health and environmental risk assessment.
This article provides a comprehensive guide to the Globally Harmonized System (GHS) of hazard classification tailored for biomedical researchers and drug development professionals.
This article provides a comprehensive guide for researchers and drug development professionals on the application of machine learning (ML) for in silico LD50 prediction.
This article provides researchers, scientists, and drug development professionals with a comprehensive guide to the principles and methodologies for converting acute toxicity data (LD50) into chronic human safety thresholds, specifically...
This article provides a comprehensive analysis for researchers and drug development professionals on the paradigm shift away from the classical LD50 animal test.
This article provides a comprehensive overview of methods for determining the No Observed Adverse Effect Level (NOAEL) from 90-day repeated dose toxicity studies, a critical component of nonclinical safety assessment.
This article provides a comprehensive comparison of two pivotal alternative methods in acute systemic toxicity testing: the Fixed Dose Procedure (FDP) and the Up-and-Down Procedure (UDP).
This article provides a comprehensive guide for researchers and toxicology professionals on determining the median lethal dose (LD50) using probit analysis.
This article provides a comprehensive overview of the OECD Guidelines for acute oral toxicity testing, tailored for researchers, scientists, and drug development professionals.
This article provides a comprehensive guide to Derived No-Effect Levels (DNELs), a cornerstone health benchmark mandated under the EU's REACH regulation.